MINNEAPOLIS, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) ("Skyline" or "the Company"), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announces the signing of a distribution agreement granting GLG Pharma, LLC ("GLG") exclusive rights to market and distribute the STREAMWAY® System in the U.K. Under the terms of the agreement, GLG will be responsible for all sales and marketing activities, including hiring and training the appropriate number of direct sales representatives to cover the 3,600 operating rooms in the U.K. Marketing is expected to begin immediately upon receipt of the CE Mark. Skyline applied for CE Mark approval to market STREAMWAY in the European Union and certain other countries in July 2016, following receipt of ISO 13485:2003 certification. "We look forward to bringing the benefits of the STREAMWAY System to healthcare professionals and facilities across the U.K. and to an even closer relationship with Skyline," said Richard Gabriel, Co-founder and Chief Operating Officer of GLG Pharma. "We have considerable experience with bringing medical products to EU facilities, which will be invaluable to our work with the STREAMWAY System," Mr. Gabriel added. In June 2016 STREAMWAY received ISO 13485:2003 certification, an internationally recognized quality standard for medical devices that is awarded when an organization demonstrates its ability to provide medical devices and related services that consistently meet customer and regulatory requirements applicable to medical devices and related services, and is a requirement for medical device clearance in Canada, the EU and a majority of other countries that require products meet EU safety, health and environmental requirements. Under the terms of an agreement announced in September 2016, GLG intends to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. Initial tests are anticipated to include cancer biomarkers and infectious diseases. The oncology test panels will feature GLG's patented inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3), which are in preclinical development for a new generation of targeted therapies.